Olanzapine or prochlorperazine added to antiemetic therapy for persistent chemotherapy-induced nausea: an NCORP phase 3 RCT
In brief
Olanzapine lowered peak nausea scores 0.59 points more than prochlorperazine
In 310 women with breast cancer and persistent nausea, adding either drug to standard antiemetics reduced average nausea during the next chemotherapy cycle compared with placebo. Olanzapine also lowered peak nausea more than prochlorperazine and improved quality-of-life scores; side effects were mostly mild, but the trial tested only one treatment cycle.
- Journal
- Journal of the National Cancer Institute (Q1)
- Published
- 13 November 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Luke J Peppone, Gary R Morrow, Riham Alieldin, Chunkit Fung, Michelle C Janelsins, Charles Kamen, et al.
- PMID
- 43021552
- DOI
- 10.1093/jnci/djag404
Why clinicians should know about it
- Picked for Oncology and Radiation Oncology (top studies of the week, 15 November 2026): Phase III randomized trial of chemotherapy-induced nausea treatment
Abstract
BACKGROUND: Despite guideline-consistent antiemetic prophylaxis, persistent chemotherapy-induced nausea remains common, and comparative phase 3 evidence for olanzapine versus prochlorperazine is limited. We evaluated whether adding olanzapine or prochlorperazine to standardized Cycle 2 antiemetic prophylaxis reduces persistent nausea compared with placebo. METHODS: In this multicenter, randomized, double-blind, placebo-controlled phase 3 trial at 23 NCORP community oncology sites (April 2018-January 2024), women 18 years or older with breast cancer receiving moderately or highly emetogenic chemotherapy who recorded a Cycle 1 nausea score of 3 or greater (1-7 scale) were randomized 1:1:1 during Cycle 2 to placebo, prochlorperazine (10 mg every 8 hours, Days 1-4), or olanzapine (10 mg once daily, Days 1-4), added to netupitant/palonosetron plus dexamethasone. The primary outcome was change in average nausea from Cycle 1 to Cycle 2; the key secondary outcome was change in maximum nausea. RESULTS: Among 1363 screened patients, 310 comprised the intention-to-treat population (placebo, 91; prochlorperazine, 110; olanzapine, 109). Compared with placebo, average nausea improved with prochlorperazine (between-group difference, -0.44; P=.01) and olanzapine (-0.57; P=.001). Olanzapine reduced maximum nausea more than prochlorperazine (difference, -0.59; P=.02) and improved FACT-G quality-of-life scores over placebo (difference, 4.91; P=.006) and prochlorperazine (5.80; P=.001). Adverse events were primarily grade 1-2, with no toxicity-related discontinuations. CONCLUSIONS: Adding olanzapine or prochlorperazine to standardized Cycle 2 antiemetic prophylaxis reduced persistent chemotherapy-induced nausea compared with placebo. Olanzapine produced greater improvement in maximum nausea and quality of life than prochlorperazine and is an effective escalation option, with prochlorperazine a reasonable alternative when olanzapine is unsuitable. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03367572.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.